Biotech Daily

Tuesday April 7, 2020

Daily news on ASX-listed biotechnology companies

*** ASX DOWN, BIOTECH UP: PROTEOMICS 22%; OPTISCAN DOWN 36%**

*** MICRO-X WINS $1.2m COVID-19 ORDERS FOR NANO X-RAY SYSTEMS**

*** CSL, TAKEDA LEAD COVID-19 'HYPERIMMUNE' ALLIANCE**

*** REDHILL: ITALY OKAY FOR OPAGANIB FOR COVID-19, ISRAELI TREATED**

*** ZELIRA: MARIJUANA ZLT-101 'EFFECTIVE FOR INSOMNIA'**

*** POLYNOVO: 'NOVOSORB BTM BEATS BURNS BENCHMARK'**

*** POLYNOVO: 'DESPITE COVID-19, Q3 SALES UP'; $9m LOAN FACILITY**

*** PROTEOMICS EXPANDS TO SARS-COV-2, RETINOPATHY, CANCER**

*** NUHEARA IQBUDS MAX US, EU, CANADA, AUSTRALASIA APPROVALS**

*** VOLPARA: 2020 'ANNUAL RECURRING REVENUE' UP 172%**

*** KAZIA: PAXALISIB 'MEANINGFUL EXTENSION OF LIFE'; FINANCE**

*** CELLMID PLEADS 'IGNORANCE' TO ASX QUERY; $6m PLACEMENT**

*** COCHLEAR: UP TO 30% COVID-19 DIRECTOR, EXECUTIVE PAY CUTS**

*** OPTISCAN PLEADS SCHULTZ TO ASX 87% QUERY**

*** ALTHEA'S PEAK PROCESSING CANADA MARIJUANA APPLICATION**

*** CRESO DELIVERS $215k OF ANIBIDIOL TO VIRBAC**

*** ESENSE-LAB TAKES $50k EVERBLU LOAN HALT TO SUSPENSION**

*** AMPLIA RELEASES 18.5m VOLUNTARY ESCROW SHARES**

*** LUMYNA BELOW 5% IN ONCOSIL**

MARKET REPORT

The Australian stock market fell 0.65 percent on Tuesday April 7, 2020, with the ASX200 down 34.5 points to 5,252.3 points.

Fourteen of the Biotech Daily Top 40 stocks were up, 11 fell, 12 traded unchanged and three were untraded. All three Big Caps were down.

Proteomics was the best, up five cents or 21.7 percent to 28 cents, with 699,290 shares traded.

Polynovo climbed 15.8 percent; Compumedics and Cynata were up more than nine percent; Pro Medicus was up 7.2 percent; Medical Developments and Next Science improved six percent or more; Volpara was up 5.6 percent; Imugene improved 4.8 percent; Nanosonics was up 3.2 percent; Universal Biosensors rose 2.9 percent; Clinuvel and Mesoblast were up more than one percent; with Neuren up 0.9 percent.

Yesterday's 82.6 percent best on no news, Optiscan, led the falls on pleading 'Schultz' to an ASX price query, down 1.5 cents or 35.7 percent to 2.7 cents, with 2.1 million shares traded.

Genetic Signatures lost 8.1 percent; Actinogen and Patrys were down more than six percent; Cochlear, Immutep and LBT fell four percent or more; Resmed was down 3.2 percent; Avita and CSL shed more than two percent; Pharmaxis and Starpharma were down one percent or more; with Opthea and Telix down by less than one percent.

MICRO-X

Micro-X says it has $1.2 million in orders for its Carestream DRX Revolution Nano x-ray system primarily for Covid-19 coronavirus imaging.

Micro-X said that the New South Wales government had placed an order for the Nano system and Melbourne's Alfred Hospital ordered an additional unit and acted as local reference site.

The company said that the purchase orders were generated by Quantum Health Group, a distribution company specializing in medical imaging equipment throughout Asia.

Micro-X said $1.0 million in orders from New South Wales and other Australian customers was "part of a planned emergency tender response to the Covid-19 pandemic".

The company said it had begun "a staged major ramp up in Nano production based on the substantial increase in demand for mobile x-ray imaging to meet the imaging needs of a Covid-19 response … [and] this demand will be sustained for some time".

Micro-X managing-director Peter Rowland said the company had seen "an explosion in demand globally for acquisition of imaging capabilities in response to the Covid-19 pandemic and the Nano is already operating in 12 countries".

"As Australian government agencies increase their state of readiness to image potentially many more Australian patients, we are very pleased that our locally developed and manufactured high-tech Nano is now helping Australians in these very challenging times," Mr Rowland said.

Micro-X was up 1.5 cents or 12 percent to 14 cents.

CSL

CSL says it will work with Osaka's Takeda Pharmaceutical Co to develop a potential plasma-derived therapy for treating Covid-19 and lead a coronavirus alliance.
CSL said that the alliance would begin "immediately" with the investigational development of one, unbranded anti-Sars-Cov-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from Covid-19.
The company said that developing a hyperimmune would require plasma donations from individuals who had fully recovered from Covid-19 and whose blood contained antibodies that could fight the novel coronavirus.
CSL said that once collected, the "convalescent" plasma would then be transported to manufacturing facilities for processing, including effective virus inactivation and removal processes, and then purified into the product.
Takeda executive Julie Kim said that collaboration meant that "we could accelerate bringing a potential therapy to market … [and] increase the potential supply" and invited organizations focusing on plasma to support or join the alliance.
CSL Behring head of research and development Bill Mezzanotte said "in addition to pooling industry resources, we will also collaborate with government and academic efforts as a single alliance whenever we can, including important activities like clinical trials".
CSL said that Frankfurt's Biotest AG, the Elstree, England-based Bio Products Laboratory, the Paris-based LFB Group (originally Laboratoire Français du Fractionnement et des Biotechnologies) and the Lachan, Switzerland-based Octapharma had joined the alliance.
CSL fell $7.91 or 2.5 percent to $311.99 with 1.2 million shares traded.

REDHILL BIOPHARMA

Israel's Redhill says Italy has approved the compassionate use of its cancer drug opaganib (formerly Yeliva or ABC294640) for Covid-19, with a patient treated in Israel.
Redhill said through partner Cosmo Pharmaceuticals NV, the Italian National Institute for Infectious Diseases allowed "immediate compassionate use of its investigational drug, opaganib, in Italy for patients with confirmed coronavirus (Covid-19) infection with life-threatening clinical manifestations".
The company said Israel had also approved compassionate use and the first patient had been treated in Israel, with discussions ongoing with US authorities and other countries.
In 2015, Redhill said the US Food and Drug Administration granted orphan designation for Yeliva for cholangio-carcinoma, or bile duct cancer (BD: Apr 5, 2015).
Today, Redhill said it planned to treat about 160 patients with life-threatening clinical manifestations in three hospitals in northern Italy
Redhill medical director Dr Mark Levitt said the expanded access program allowed the treatment of patients at high risk of developing pneumonia and those with pneumonia, including acute respiratory distress syndrome, secondary to Sars-Cov-2 infection.
The company said that a total of 131 subjects had been dosed with opaganib to date in uS studies, establishing safety and tolerability.
Redhill said that opaganib was a first-in-class, oral, sphingosine kinase-2 (SK2) selective inhibitor with anticancer, anti-viral and anti-inflammatory activities, targeting multiple oncology, inflammatory and gastrointestinal indications.
The company said pre-clinical studies supported the potential role of SK2 in the replication-transcription complex of positive-strand single-stranded RNA viruses, similar to coronavirus, and its inhibition may potentially inhibit viral replication.
On the Nasdaq, Redhill was up 90 US cents or 18.91 percent to $US5.66 ($A9.28) with 1.8 million shares traded.

ZELIRA THERAPEUTICS

Zelira says its 23-patient, phase Ib/IIa trial of marijuana-derived ZLT-101 has shown safety and statistical significance for reduction of chronic insomnia.

Zelira said that the randomised, double-blind, cross-over trial treated patients for 14 nights with ZTL-101 and 14 nights of placebo, separated by a one-week washout period at the University of Western Australia Centre for Sleep Science.

The company said that the primary endpoint of insomnia severity index (ISI) showed an average 26 percent reduction for the low dose (0.5ml of 11.5mg cannabinoids) and high dose (1.0ml of 11.5mg cannabinoids) ZLT-101 groups compared to placebo, with the high dose achieving a 36 percent reduction.

Zelira said that the placebo ISI score was 18.0 compared to the low dose drug score of 14.8 ($p < 0.05$) and high dose ISI score of 11.1 ($p < 0.001$).

The company said that for the secondary endpoint of total sleep time, the low dose group exceeded placebo by 28 minutes ($p < 0.05$) and the high dose ZLT-101 group by 42 minutes ($p < 0.001$).

Zelira said that the decrease in wake time after sleep onset showed a non-significant reduction of 9,52 minutes comparing low dose to placebo, but a significant 12.31 minutes for the high dose group ($p < 0.05$).

Zelira chief executive officer Dr Richard Hopkins told Biotech Daily that there was a clear dose response relationship and “a number of quality of life measures all pointed in the right direction”.

Dr Hopkins said that patients receiving ZLT-101 compared to placebo generally felt more rested on waking with the high dose group reporting a significant difference compared to placebo ($p < 0.001$) while the low dose was not significant.

Dr Hopkins said that Zelira intended to market ZLT-101 in Australia by October 2020 and it could begin steps to licence the product in the US from today.

Dr Hopkins said the company would maintain its focus on insomnia and was currently designing a phase IIb trial extending the time period for patients receiving ZLT-101, to be followed by a phase III trial.

Zelira said that ZTL-101 was safe, with participants reporting “only minor adverse events” including dry mouth and headache with 96 percent of symptoms resolving by the next morning.

The company said that patients “tolerated the maximal dose well”.

University of Western Australia Centre for Sleep Science director and principal investigator Prof Peter Eastwood said the study was “the most rigorous clinical trial ever undertaken to assess the therapeutic potential of medicinal cannabis to treat the symptoms of chronic insomnia”.

“The fact that ZLT-101 treatment achieved statistically significant, dose responsive improvements across a broad range of key insomnia indices is impressive, particularly given the relatively short two-week dosing window,” Prof Eastwood said.

“The significant improvement in subjective sleep quality and feelings of waking up rested as reported by participants was particularly notable,” Prof Eastwood said.

“Positive patient experiences with minimal side-effects are critical to the success of any insomnia drug and highlights the potential for ZTL-101 to address a key area of unmet need,” Prof Eastwood said. “It is likely that further improvements in efficacy could be achieved by dosing over a longer period and potentially at higher doses.”

“Taken together, these results are comparable to other approved insomnia therapies at a similar stage of development and suggests that ZLT-101 can be developed as a novel treatment for chronic insomnia,” Prof Eastwood said.

Zelira was up 0.8 cents or 22.2 percent to 4.4 cents with 4.7 million shares traded.

POLYNOVO

Polynovo says its Novosorb biodegradable temporizing matrix split thickness skin graft 'take' percentage is significantly greater than the benchmark for burns (p = 0.031).

Polynovo said its 12-month Conformité Européenne (CE) mark prospective, multi-centre, single-arm, open label, pre-market trial administered Novosorb Biodegradable Temporizing Matrix (BTM) to 30 deep burn injury patients aged 18 to 70 years old in France and Australia.

The company said the primary endpoint was to assess the percentage of split-thickness skin graft (SSG) take, or the percentage of device or skin graft incorporated into the wound bed, over BTM within seven to 10 days after grafting as a proportion of the total amount of BTM applied.

Polynovo said that the target value was 77 percent SSG take, which had been derived from results published in the literature for other dermal matrices.

The company said that 26 patients were assessed and showed a median of 88.6 percent SSG take and a mean of 81.9 percent SSG take.

Polynovo said that that "after transformation to allow for the non-normal distribution of the data, the mean percentage SSG take over BTM [after seven to 10 days] was significantly greater than 77 percent (p = 0.031) thereby demonstrating superiority".

The company said that wound closure was assessed at seven to 10 days after skin grafting and three, six, and 12 months after BTM applications with mean values of 90.4 percent, 99.9 percent, 99.8 percent and 100 percent respectively.

Polynovo said "these results provide further clinical evidence supporting the role of BTM in providing temporary wound closure and reconstruction of a dermis for subsequent would healing".

The company said that the secondary endpoint was the percentage of BTM take at the time of skin grafting as a proportion of the BTM implanted and the results showed a mean BTM take percentage of 88.8 percent with a median of 95 percent.

Polynovo said the BTM take percentage showed "that there was effective integration of the BTM assessed at the time of sealing membrane removal and skin grafting".

The company said patient safety was monitored and no new risks were identified.

Polynovo said there were infections in 10 patients during the BTM integration and one patient after skin grafting, with three patients with serious device-related infections, but all infections were treated and resolved with successful skin grafts.

Polynovo chief executive officer Paul Brennan said that "the results of this full thickness burn trial reinforce what surgeons across the world are reporting; that BTM is 'robust', a relatively simple product to use, performs extremely well in the most challenging of case applications and seems to be resilient even if there is an infection".

"The study supports our CE mark claims and adds to the high level of data that clinicians request to support their decision to make BTM their preferred choice of dermal matrix," Mr Brennan said. "Achieving a superior result to the benchmark is often demonstrated by our clinical and functional outcomes reported by surgeons and patients around the world."

Polynovo chairman David Williams said that "while the burn trial was ultimately not needed for [the Australian Register of Therapeutic Goods] or CE approval, the excellent results, while expected, will strengthen our marketing to surgeons".

The company said that the trial began in 2015 when a successful clinical trial was required for making an Australian Register of Therapeutic Goods and Conformité Européenne (CE) mark application, but the Federal Government introduced the Priority Review Designation pathway and in 2018 the company gained the ARTG listing, with CE mark approval on December 13, 2019 (BD: Aug 14, 2018; Dec 13, 2019)

Polynovo was up 26.5 cents or 15.8 percent to $1.94 with 12.7 million shares traded.

POLYNOVO

Polynovo says sales for the three months to March 31, 2020 were up 165.7 percent $4.49 million and Covid-19 would not “have any material impact on the business”.

Polynovo said sales in the month of March 2020 were up 173.7 percent to $1.76 million compared to March 2019, including “a monthly record sales result for the US”.

Polynovo chief executive officer Paul Brennan said that the Covid-19 pandemic had limited its “sales team having face to face access in most regions … [but] our teams have been using platforms like Zoom to conduct product presentations”.

Separately, the company said it had a $9.3 million loan facility with the National Australia Bank to fund a hernia cleanroom construction, manufacturing equipment and other capital expenditure.

“Cash, surplus to those needs, along with our existing $7.4 million cash will be used for working capital and growth”, Mr Brennan said.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says it has expanded its diagnostics development pipeline to include tests for Sars-Cov-2, diabetic retinopathy, cancer, oxidative stress and plant dieback.

Proteomics said it had begun its research program for a test for severe acute respiratory disease coronavirus 2 (Sars-Cov-2) “to develop a rapid diagnostic test for the identification of the Sars-Cov-2 virus, and to isolate biomarkers that gave insights into the progression of the Covid-19 disease”, but provided no further details.

Proteomics chief executive officer Dr Richard Lipscombe told Biotech Daily that the company was “working with clinical groups in Perth”.

In its media release to the ASX Proteomics said that along with the commercialization of Promarkerd for diabetic kidney disease, previously announced programs included diagnostics for endometriosis, giardia, asthma and chronic obstructive pulmonary disease.

The company said the new programs included diabetic retinopathy with a “discovery study pending”, in-licencing discussions for biomarkers for cancer with a proof-of-concept study completed and clinical validation pending.

Proteomics said that it was involved in discussion with the Australian Research centre for Personalised Therapeutics and other consortium members for a discovery project in an area of significant unmet medical need.

The company said it was involved in commercialization discussions on markers for oxidative stress, known as '2-tag' technology, as well as plant dieback caused by Phytophthora cinnamomic, which had “already infected more than 1 million hectares of Western Australian bushland …[as well as] premium crops such [as] avocados, macadamias and pineapples” costing the Australian economy $160 million a year for damage to natural vegetation alone.

Proteomics was up five cents or 21.7 percent to 28 cents.

NUHEARA

Nuheara says its Iqbuds Max hearing buds have been approved in the European Union, US, Canada, Australia and New Zealand.

Nuheara said it had approvals from the US Federal Communication Commission, Industry Canada, Australia and New Zealand Regulatory Compliance Mark and Conformité Européenne (CE) mark.

Nuheara was up 0.3 cents or 20 percent to 1.8 cents with 6.8 million shares traded.

VOLPARA HEALTH TECHNOLOGIES

Volpara says that annual recurring revenue from its breast cancer diagnostics for the year to March 31, 2020 was up 171.5 percent to $NZ18 million ($A17.5 million).
Volpara said it had “at least one software product being used in the screening of [about] 27.1 percent of US women for breast cancer”, meeting its target for the year to March 31, the company had more than $NZ31 million in cash at March 31 and no debt.
The company said it expected the Covid-19 pandemic to affect the business in the year to March 31, 2021, “but the exact quantum remains to be seen”.
Volpara chief executive officer Dr Ralph Highnam said that despite Covid-19 the company had “a very strong” three months to March 31, meeting and exceeding targets, including an increase in annual recurring revenue of 172 percent, including a contribution from the Mammography Reporting Systems Inc acquisition.
“We’ve been fortunate to have been a very virtual and resilient company from the start due to our location in New Zealand,” Dr Highnam said. “Our ability to work from home, proven cloud-based products, an outstanding US sales team have all helped beat the targets.”
“Despite the confidence in the sale pipeline … the company is being prudent by undertaking a review of operating expenses to reflect the new world in which we are operating and the anticipated uncertainty in the US market,” Dr Highnam said.
“For example, some breast cancer screening sites are in lockdown for varying periods of time,” Dr Highnam said.
“These are unprecedented times, but with 500,000 women a year dying from breast cancer, screening is a service you can only disrupt for so long, or else you risk the rise of advanced breast cancers and even higher mortality rate,” Dr Highnam said.
“We are confident that screening will ramp back up as the world learns how to deal with Covid-19,” Dr Highnam said.
Volpara was up 6.5 cents or 5.6 percent to $1.23 with one million shares traded.

KAZIA THERAPEUTICS

Kazia says an interim analysis of nine patients in its ongoing study of paxalisib, or GDC-0084, for glioblastoma shows median overall survival of 17.7 months.
Kazia said the overall survival represented “a clinically meaningful extension of life when compared to the 12.7 months associated with the existing standard of care, temozolomide”.
The company said the data came from its ongoing 30-patient phase II study of paxalisib, which separated patients into a nine-patient part A dose escalation cohort, and a 21-patient part B cohort.
Kazia said all 30 evaluable patients showed a median progression-free survival of 8.5 months, compared to the 5.3 months associated with the standard-of-care temozolomide, with the longest-treated patient progression-free 19 months after diagnosis.
Kazia chief executive officer Dr James Garner said that “the gold standard for any new cancer treatment is the ability to extend life, an especially challenging goal in a disease such as glioblastoma, and this data provides out first evidence that paxalisib may achieve this objective”.
“There have not been any new drug treatments for newly-diagnosed glioblastoma patients for over 20 years and we aspire to change that situation,” Dr Garner said.
Kazia said it expected further data by the end of 2020 and final data by July 2021.
Separately, Kazia requested a trading halt pending “an announcement on a financing transaction” and trading would resume on April 15, 2020 or on an earlier announcement.
Kazia last traded at 44.5 cents.

CELLMID

Cellmid says that “it was not understood” that social media posts by chief executive officer Maria Halasz in a trading halt should not be made before informing the ASX.

The ASX said that Cellmid chief executive officer Maria Halasz posted information about Covid-19 tests on the Twitter and Instagram social media sites on March 23 ahead of the March 27 news of the distribution rights to a Covid-19 antibody test.

Cellmid requested a trading halt on Friday March 20 “pending the outcome of ongoing negotiations in relation to a potential material contract” and on Tuesday March 24, extended the trading halt to a suspension (BD: Mar 20, Mar 24, 2020).

On Friday, March 27, at 7.01pm after the market had closed for the weekend, Cellmid said it had an agreement to distribute Guangzhou Wondfo Biotech’s antibody test for Covid-19, the disease caused by Sars-Cov-2, and in trading on March 30, Cellmid climbed 213.1 percent to 31 cents with 24.0 million shares traded (BD: Mar 30, 2020).

On Thursday April 2, Cellmid requested a trading halt “pending the release of an announcement regarding a capital raising” which yesterday was extended to a suspension (BD: Apr 2, 6, 2020).

Last night after the market closed at 6.15pm, Cellmid posted its response to the ASX query of that same day.

Today, the company announced a $6 million placement at 22 cents, with a share plan to raise a further $1 million.

The ASX query noted the Cellmid announcement titled ‘Cellmid Signs Covid-19 Rapid Diagnostic Supply Agreement’ released to the ASX on March 27 in which Cellmid disclosed the Covid-19 test supply agreement with Guangzhou Wondfo Biotech and the posts made by Ms Halasz on her Twitter and Instagram accounts on March 23, which were subsequently deleted from Twitter and Instagram:

“Important update $CDY shareholders. I’m negative! I know this because I was able to test myself with the first validated rapid diagnostic test for #Covid-19.”

The ASX said that some Twitter and Instagram users subsequently reposted or shared the posts on Twitter and the internet discussion forum Hotcopper.

The ASX noted Listing rule 3.1: “Once an entity is or becomes aware of any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity’s securities, the entity must immediately tell ASX” and Listing rule 15.7: “An entity must not release information that is for release to the market to any person until it has given the information to ASX and has received an acknowledgment that ASX has released information to the market.”

Cellmid said the March 23 tweet “was a personal one showing that [Ms Halasz] had taken a rapid test, no details in relation to a supply agreement were disclosed”.

“In response to a comment on that tweet Ms Halasz advised that [Cellmid] was the licenced distributor of the tests,” Cellmid said.

“This response was sent at a time Ms Halasz believed the company had complied with its disclosure obligations … [and] the company’s shares were in a trading halt ensuring that there could be no trading on an uninformed basis, the supply agreement had been finalized and the announcement providing details of the agreement and to release the company from the trading halt had been provided to the ASX,” the company said.

Cellmid said “it was not understood that the restrictions stated in the Social Media Policy and in ASX Listing Rule 15.7 remained applicable during a trading halt”.

Cellmid said that director Dennis Eck had applied for $950,000 in shares and Ms Halasz had applied for $50,000, subject to shareholder approval, and the proceeds would fund the roll out of the Covid-19 diagnostics and general working capital.

Cellmid was up 8.5 cents or 31.5 percent to 35.5 cents with 11.6 million shares traded.

COCHLEAR

Cochlear says that chief executive officer Dig Howitt and non-executive directors will take a 30 percent pay cut for three-months due to the Covid-19 pandemic.
Cochlear said that senior executives would lose 20 percent of their base salaries and Mr Howitt would not receive any short-term incentives for the year to June 30, 2020.
Cochlear chairman Rock Holliday-Smith said that the company had faced an “expected temporary decline in demand, caused by Covid-19”.
“Cochlear is making every effort to retain its highly skilled workforce and continue to invest in its [research and development] programs throughout the Covid-19 pandemic,” Mr Holliday-Smith said. “Given the significant impact of Covid-19 to sales revenue, we believe a temporary reduction in pay to the board and senior management is an appropriate measure that helps shares the burden with our employees and other stakeholders.”
Cochlear fell $8.19 or 4.3 percent to $183.18 with 376,786 shares traded.

OPTISCAN IMAGING

Optiscan has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.
The ASX said the company’s share price rose 86.96 percent from a low of 2.3 cents on April 3 to a high of 4.3 cents on April 6, 2020.
Optiscan fell 1.5 cents or 35.7 percent to 2.7 cents with 2.1 million shares traded.

ALTHEA GROUP HOLDINGS

Althea says its wholly owned subsidiary, Peak Processing Solutions, has completed its Health Canada marijuana standard processing licence application.
Althea said the processing licence would allow operations to start at its Tecumseh, Ontario-based 3,716 square metre pharmaceutical-grade marijuana processing facility.
The company said that the facility would produce a range of medicinal marijuana products for Althea, reducing its cost of goods.
Althea was up six cents or 20.7 percent to 35 cents with 3.1 million shares traded.

CRESO PHARMA

Creso says it delivered $215,000 of marijuana-based Anibidiol Plus to its Carros, France-based European distributer, Virbac SA International.
Creso said Anibidiol Plus was medication for small to large sized pets “to support the reduction of stress and help animals’ nervous systems to function well”.
Creso was up half a cent or 8.2 percent to 6.6 cents with 2.6 million shares traded.

ESENSE-LAB

Esense has requested a voluntary suspension to follow a trading halt in relation to a $50,000 working capital loan from Everblu Capital Pty Ltd.
Last week, Esense said it had a $50,000 loan from Everblu Capital, repayable at 0.4 cents per Chess depository interest (CDI), with one free attaching option per two CDIs exercisable at 1.0 cent each, expiring 18 months from issue (BD: Apr 3, 2020).
Today, Esense said it expected to resume trading on April 9, 2020, or on an earlier announcement.
Esense last traded at 0.7 cents.

AMPLIA THERAPEUTICS

Amplia says it will release 18,460,308 shares from voluntary escrow on May 4, 2020.
Amplia said the shares were issued to the vendors of the then privately owned Amplia Therapeutics as consideration for the acquisition of the company and its focal adhesion kinase programs (BD: Mar 28, Apr 26, 2018).
According to the company's most recent Appendix 3B, following the release it will have 66,463,185 shares available for trade.
Amplia was untraded at 5.6 cents.

ONCOSIL MEDICAL

The London and Luxembourg-based Lumyna Investments says it has ceased its substantial shareholding in Oncosil.
Last month, Lumyna Investments said it had become substantial in Oncosil with 46,358,040 shares or 7.35 percent of the company (BD: Mar 18, 2020).
Today, Lumyna said that it bought and sold shares between March 26 and April 3, 2020 with the single largest sale on April 3 of 11,730,880 shares for $102,597 or 0.9 cents each, when the shares traded between 12 and 14 cents.
Oncosil was unchanged at 13 cents with 1.3 million shares traded.